Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights:
- First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
- Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast
- Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea
- Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs
- Clinical Trials Insight by Company, Country, Indication
- Patent Insight of Peptide Drug Conjugates
- Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates
The use of peptide as clinical therapeutics is dated back with the development of first recombinant insulin for the management of diabetes. Due to their extremely small size and versatile nature, researchers have exploited the use of peptides in the management of several chronic disorders including cancer. Due to their high efficacy and specificity towards the specific receptors present on cancer cells, researchers have used the peptides in the delivery of the drug to target cancer cell.
Peptide drug conjugates are the emerging class of drugs, formed through the covalent attachment of peptide sequence to a drug via a cleavable linker. The development of this novel class of drug has shown to confer several advantages in comparison to conventional cancer therapies. As peptides are readily cleaved by proteolytic enzymes, hence they are rapidly cleared from kidney. Furthermore, their low molecular weight leads to enhanced penetration into solid tumors resulting in robust anti-tumor response. Apart from this, the therapy can also be used in patients who are unresponsive to other currently available therapies, thus increasing their uptake in market.
To date, only peptide drug conjugate drug have been approved for the management of cancer. Melphalan flufenamide (melflufen, Pepaxto) developed by Oncopeptides is a peptide conjugated alkylating drug which has recently received approval in US for the management of relapsed or refractory multiple myeloma. Within short span of approval, the drug has shown robust sales in US which has gathered a lot of attention in the market. By analyzing the high adoption rates and their encouraging clinical response, several pharmaceutical companies including Astrazencea, Bicycle Therapeutics, Theratechnologies and others have invested a large amount for the development of novel peptide drug conjugates in management of wide range of cancers.